Shandong Weigao Group Medical Polymer Co Ltd (1066)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 21 Oct 2026
Key indicators
| Last close | HKD 3.180 |
|---|---|
| 52-week range | 2.920 – 5.705 |
| Return, 1 month / 3 months | +0.6% / −2.8% |
| Return, 1 year / 3 years | −44.5% / −48.5% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 35.7% |
| Worst drawdown (1 year) | -45.1% |
| Average daily value traded | 34.56M HKD |
| Dividend yield | 5.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Shandong Weigao Group Medical Polymer is a Chinese maker of medical consumables and devices based in Weihai, in Shandong province. It produces disposable hospital supplies such as infusion sets, syringes, blood bags and wound-care dressings, along with orthopaedic implants, blood purification products and other clinical devices. Its customers are hospitals, clinics and healthcare distributors, mainly in China, and it also supplies medical products to overseas markets through its own brands and partnerships.
The shares are listed on the Hong Kong Stock Exchange in Hong Kong under the code 1066, and the price on this page is in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Shandong Weigao Group Medical Polymer Co Ltd (1066) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 3.180 on 21 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 1,084 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 44.5% and over the last three months it fell 2.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 38 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -17.5% | ||
| From 52-week high | -43.4% | ||
| Momentum | 43 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -2.8% | ||
| 6-month return | -12.3% | ||
| 12-month return, skipping the last month | -44.9% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 35.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -45.1% | ||
| Liquidity | 84 · Strong | Trades actively. | |
| Average daily value traded | 34.56M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 57 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.5% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −6.2% |
|---|---|
| 1 month | +0.6% |
| 3 months | −2.8% |
| 6 months | −12.3% |
| 1 year | −44.5% |
| 3 years | −48.5% |
| 5 years | – |
Signals
| 50-day / 200-day average | 3.297 / 3.853 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.103 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jun 2026 | HKD 0.0688 |
| 21 Oct 2025 | HKD 0.1061 |
| 2 Jun 2025 | HKD 0.1344 |
| 18 Oct 2024 | HKD 0.1009 |
| 3 Jun 2024 | HKD 0.1035 |
| 19 Oct 2023 | HKD 0.0800 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.